Trial Profile
A prospective, multicentre study to evaluate the efficacy and safety of Ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without ribavirin in patients with genotype 1 hepatitis C and advanced liver disease in a real-world setting
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Jul 2017
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C; Liver disorders
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Acronyms Rev1tal
- Sponsors AbbVie
- 18 May 2016 New trial record
- 17 Apr 2016 Preliminary interim analysis (n=172) presented at The International Liver Congress™ 2016.